Home › Alcohol Use Disorder (AUD) › NCT07772960
Semaglutide Dose Effects on Metabolic and Stress Hormone, Craving and Alcohol Use Outcomes
RecruitingPhase 1
Who can join
Ages 18 to 68 · All sexes
Full eligibility criteria
Inclusion Criteria: * Male and females ages 18-60 and BMI in 30-49.9 kg/m2; * regular weekly alcohol use (at least 3X/week) prior to admission; * must meet current DSM-V criteria for moderate to severe Alcohol Use Disorders (AUDs) using SCID-I for DSM-V; * Good health as verified by screening and physical examination; * Able to read English and complete study evaluation; * Able to provide informed written and verbal consent. Exclusion Criteria: * Meet current criteria for moderate to severe substance use disorders from abuse of any another psychoactive substance, excluding nicotine; * Current use of opiates; * Current use of psychiatric medications, including benzodiazepine-based sedatives/anxiolytics and anticonvulsants, non SSRI antidepressants, oral prescription analgesics (other than non-steroidal anti-inflammatory drugs), acamprosate, naltrexone, antabuse, baclofen, varenicline; * Psychotic or otherwise severely psychiatrically disabled (i.e., suicidal, homicidal, current mania); * Endocrine or immune disorders, including diagnosis of diabetes (T2D or T1D) by American Diabetes Association (ADA) criteria or a history of HgbA1c \>6.5% and on current medications for T2D treatment; * Significant underlying medical conditions, including history of pancreatitis, acute kidney injury, medullary thyroid cancer, or MEN syndrome, as well as other cerebral, renal, thyroid or cardiac pathology that would preclude study participation; * Current use of any anti-obesity medications; * Prior history of bariatric surgery or current intragastric balloon; * Current participation in structured meal replacement or weight loss program; * Weight loss of \>=10% over the preceding 6 months; * Women who are pregnant, nursing or refuse use of reliable form of birth control.
About the study
This study will examine two doses of 1.0 mg and 2.0 mg of Semaglutide versus placebo in patients with Alcohol Use Disorder (AUD) and Obesity (Ob) to assess if these doses improve alcohol craving, stress and alcohol use outcomes.
What is being tested
- Placebo (other)
- Semaglutide 1.0 mg (drug)
- Semaglutide 2.0 mg (drug)
Sponsor: Yale University · Participants: 90 · Started: Oct 1, 2026
Contact the study team
- RAJITA SINHA, PHD · Phone: 2037375805
Official record on ClinicalTrials.gov — NCT07772960
Locations in the U.S.
| Connecticut | Yale Stress Center, New Haven Yale Stress Center, New Haven |
Conditions
From ClinicalTrials.gov, data retrieved Nov 15, 2026. Each study sets its own eligibility; the study team decides who can join.